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The two articles in this edition of CME follow up on those in 
the previous edition, i.e. epidemiology/aetiology and diagnosis of 
community-acquired pneumonia (CAP) in children.[1,2] The articles 
in this issue cover recommendations on management and prevention 
of childhood pneumonia.[3,4]
Management of a child with cough or difficult breathing needs a 
context. Most coughs are due to upper respiratory tract infections 
(URTIs) – almost all are viral in aetiology and rarely require 
antibiotics. The World Health Organization (WHO) added to that 
strategy, recommending that children with acute cough, who are 
not ‘fast breathing’, have by definition a URTI and do not need 
anti biotics.[5] Two major consequences as a result of inappropriate 
antibiotic use include emergence of antimicrobial resistance and 
dysbiosis of the human microbiome. Both of these contribute to 
morbidity and mortality.
We are in the midst of the COVID-19 pandemic and, unfortunately, 
COVID-19 overlaps with seasonal upper and lower respiratory 
tract infections. In South Africa (SA), autumn is characterised 
by respiratory syncytial virus (RSV) and rhinovirus paediatric 
bronchiolitis, followed by seasonal influenza outbreaks.[6] These 
conditions may be clinically indistinguishable from COVID-19. 
Respiratory viruses are the leading cause of pneumonia, including 
two-thirds of young children requiring hospitalisation.[1] RSV 
also causes approximately one-third of all hospitalisations due 
to pneumonia. Other viruses associated with pneumonia include 
influenza virus, parainfluenza virus, human metapneumovirus, 
rhinovirus and adenovirus. 
Judicious utilisation of antibiotics is fundamental, especially with 
the ever-increasing resistance of common pathogens to widely used 
antimicrobial agents. There is no evidence that antibiotics influence 
the course of milder forms of COVID-19.
In contrast, antibiotics for bacterial pneumonia or severe 
pneumonia are life saving. Globally, ~800 000 children die each year 
from pneumonia and lack of access to care or antibiotic therapy; in 
SA, ~4 000 children die per year from pneumonia. Given advances 
in prevention, including pneumococcal conjugate vaccine (PCV) 
and Haemophilus influenzae type b conjugate vaccine (HibCV), the 
spectrum of bacteria causing pneumonia has changed, reflected by an 
increased prevalence of non-typable H. influenzae and Staphylococcus 
aureus. Co-infection with bacteria or other respiratory viruses is 
common in hospitalised children. Furthermore, Mycobacterium 
tuberculosis often occurs in SA children hospitalised with CAP or 
those with pneumonia and household or community exposure. The 
current revised strategy for antibiotic treatment of CAP, outlined in 
this edition of CME, includes:[3]
• Oral amoxicillin (45 mg/kg/dose bid; 90 mg/kg/day) is the 
treatment of choice for children with pneumonia treated in the 
ambulatory setting.
• Treatment duration should be 5 days for children managed as 
outpatients, with review in 3 days to evaluate response.
• Treatment should be switched to co-amoxiclavulanate if there 
is clinical deterioration, and the child should be referred for 
investigation.
• Co-amoxiclavulanate (intravenously or orally) is the treatment of 
choice for children >1 month of age with severe pneumonia, who 
require hospitalisation. 
• Treatment duration should be 5 days for severe pneumonia. 
Childhood vaccination is the most effective strategy for limiting 
CAP and inappropriate antibiotic use. Vaccination is one of the 
most successful strategies that promotes public health, and millions 
of people are alive today because they were vaccinated during 
childhood. Critical childhood vaccines to prevent CAP include 
bacillus Calmette-Guérin (BCG) vaccine at birth; 13-valent PCV; 
HibCV recommended (as part of a combination vaccine) at 6, 10 and 
14 weeks of age, and a booster dose at 15 - 18 months of age; pertussis 
vaccine at 6, 10 and 14 weeks of age, and a booster dose at 15 - 18 months 
of age; and measles vaccine.[4] 
An important vaccine that is readily available in Africa and that 
should be administered to both children and adults, is the influenza 
vaccine. Unfortunately, relatively few South Africans are vaccinated 
for influenza. Although influenza vaccinations are recommended for 
everyone, the following individuals should be vaccinated annually: 
• children at high risk of complications from influenza, including 
those with chronic pulmonary, cardiac, renal, hepatic, endocrine, 
neurological, metabolic or immunological diseases, which increase 
the risk of severe influenza
• children receiving chronic aspirin therapy
• anyone who has regular contact with young children or high-risk 
individuals.
Some countries recommend routine immunisation for all children 
between the ages of 6 and 59 months. 
Africans celebrated Vaccination Week from 24 to 30 April 2020. 
The objective of this initiative was to create 
awareness of vaccines that can protect 
children, and especially women, from 
specific preventable diseases. ‘Vaccines 
work, do your part.’[7]
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